1. Home
  2. PRTA vs BETR Comparison

PRTA vs BETR Comparison

Compare PRTA & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.82

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

HOLD

Current Price

$38.30

Market Cap

538.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTA
BETR
Founded
2012
2014
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
539.9M
538.7M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PRTA
BETR
Price
$10.82
$38.30
Analyst Decision
Buy
Buy
Analyst Count
9
1
Target Price
$19.00
$40.00
AVG Volume (30 Days)
453.1K
517.9K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$814,000.00
N/A
Revenue This Year
$1,111.38
$54.06
Revenue Next Year
N/A
$66.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$10.81
52 Week High
$11.69
$94.06

Technical Indicators

Market Signals
Indicator
PRTA
BETR
Relative Strength Index (RSI) 67.15 55.60
Support Level $9.69 $26.89
Resistance Level $10.90 $41.23
Average True Range (ATR) 0.40 3.54
MACD 0.10 0.09
Stochastic Oscillator 96.87 49.90

Price Performance

Historical Comparison
PRTA
BETR

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

Share on Social Networks: